Search Results for: Ibrutinib – Page 3

ASH 2022: Time to Next Therapy with Acalabrutinib vs Ibrutinib

This real-world study found that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib were more likely to need to change therapies or add an additional therapy compared with patients treated with ibrutinib.

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL / SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

The first interim analysis of the Phase 2 HOVON 158/Next Step Trial was conducted halfway through a 15-month course of treatment with ibrutinib and venetoclax. As compared to baseline, PET-CT scanning showed a decrease in metabolic activity in all but one patient. However, despite the decrease in metabolic activity and, in some cases, normal metabolic activity on PET-CT scans, several patients had persistently enlarged lymph nodes.

ASH 2022: Dr. Paolo Ghia on Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) who Received First-Line Treatment with Ibrutinib

Targeted therapies have greatly improved survival outcomes for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). For example, Ibrutinib is so effective at controlling CLL / SLL that the overall survival of patients treated with first-line ibrutinib is no different from that of the general population.

Didn't find what you where looking for?

Try our advanced search page!